Back to News
Market Impact: 0.15
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Outlook Therapeutics announced Greg DiPasquale as chief commercial officer on Friday. The company is developing and commercializing LYTENAVA for retinal diseases; the article gave no further details about the appointment or its expected impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
OTLK0.10
More News
- ‘I drive a Tesla’: After Elon Musk said he’d lose his job, Delta CEO Ed Bastian says there’s ‘no tit for tat’ as airline unveils earnings miss
- Trump created a committee to dig into the Fed's Lisa Cook. What is it and what comes next?
- ‘Indentured servants’: US green card move will hit thousands of IT workers
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Trump launches probe into Federal Reserve Governor Lisa Cook
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Financial Research Benchmarks: What the Scores Mean
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper